<SEC-DOCUMENT>0001178913-25-000959.txt : 20250320
<SEC-HEADER>0001178913-25-000959.hdr.sgml : 20250320
<ACCEPTANCE-DATETIME>20250320171419
ACCESSION NUMBER:		0001178913-25-000959
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250320
FILED AS OF DATE:		20250320
DATE AS OF CHANGE:		20250320

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Chemomab Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001534248
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				813676773
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38807
		FILM NUMBER:		25757754

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002
		BUSINESS PHONE:		972-77-331-0156

	MAIL ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Anchiano Therapeutics Ltd.
		DATE OF NAME CHANGE:	20180906

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioCancell Ltd.
		DATE OF NAME CHANGE:	20111104
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2532900.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: zk-global
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><br>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Washington, D.C. 20549</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">FORM 6-K</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">PURSUANT TO RULE 13a-16 OR 15d-16</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">For the month of: March 2025</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">Commission File Number: 001-38807</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</div>
    <div style="text-align: center; line-height: 1.25;">(Translation of registrant&#8217;s name into English)</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Kiryat Atidim, Building 7, Tel-Aviv, Israel</div>
    <div style="text-align: center; line-height: 1.25;">(Address of principal executive offices)</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">Form 20-F &#9746; Form 40-F &#9744; <br>
    </div>
  </div>
  <br>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div>&#160;
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><u>CONTENTS</u></div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On November 15, 2024, Chemomab Therapeutics Ltd. (the &#8220;Registrant&#8221;) filed a prospectus supplement under its Sales
      Agreement (the &#8220;Sales Agreement&#8221;) with Roth Capital Partners, LLC, dated October 16, 2023. A copy of the opinion of Meitar | Law Offices relating to the legality of the issuance and sale of the Ordinary Shares underlying the ADSs that may be sold
      pursuant to the Sales Agreement is attached as Exhibit 5.1 hereto.</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Registrant&#8217;s Registration
      Statements on Form F-3 (File No. 333-275002, 333-281750 and 333-255249) and Form S-8 (File Nos. 333-266868, 333-259489, 333-237247 and 333-232757), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this
      Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="zfeaca624cbbb4254a748015572744e93" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 12%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25; font-weight: bold;">Exhibit No.</div>
          </td>
          <td style="width: 0.88%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 87%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25; font-weight: bold;">Description</div>
          </td>
        </tr>
        <tr>
          <td style="width: 12%; vertical-align: top;">
            <div style="line-height: 1.25;"><a href="exhibit_5-1.htm">5.1</a></div>
          </td>
          <td style="width: 0.88%; vertical-align: top;"><a href="exhibit_5-1.htm"><br>
            </a></td>
          <td style="width: 87%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;"><a href="exhibit_5-1.htm">Opinion of Meitar | Law
                Offices</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 12%; vertical-align: top;">
            <div style="line-height: 1.25;"><a href="exhibit_5-1.htm">23.1</a></div>
          </td>
          <td style="width: 0.88%; vertical-align: top;"><a href="exhibit_5-1.htm"><br>
            </a></td>
          <td style="width: 87%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;"><a href="exhibit_5-1.htm">Consent of Meitar | Law
                Offices (contained in Exhibit 5.1)</a></div>
          </td>
        </tr>

    </table>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><u>SIGNATURE</u></div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
      signed on its behalf by the undersigned, thereunto duly authorized.</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="z81a049a8c58946f6b02fa80e914ae2f0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="vertical-align: top;" colspan="2">
            <div style="line-height: 1.25; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="vertical-align: top;" colspan="2">
            <div style="line-height: 1.25;">(Registrant)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">Date: March 20, 2025</div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="line-height: 1.25;">By:</div>
          </td>
          <td style="width: 46%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25; font-style: italic;">/s/ Sigal Fattal</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="line-height: 1.25;">Name:</div>
          </td>
          <td style="width: 46%; vertical-align: top;">
            <div style="line-height: 1.25;">Sigal Fattal</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="line-height: 1.25;">Title:</div>
          </td>
          <td style="width: 46%; vertical-align: top;">
            <div style="line-height: 1.25;">Chief Financial Officer</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;">&#160;</div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>exhibit_5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: zk-global
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div>
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div>
      <div style="text-align: right; line-height: 1.25;"><font style="font-weight: bold;"><u>Exhibit 5.1</u></font>&#160;</div>
      <div style="text-align: center; line-height: 1.25;"><img src="image00001.jpg"><br>
        &#160;</div>
      <div style="text-align: right; line-height: 1.25;">November 15, 2024</div>
      <div style="text-align: right; line-height: 1.25;">&#160; <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 100%; vertical-align: top;">
              <div style="line-height: 1.25;">Chemomab Therapeutics Ltd.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">
              <div style="line-height: 1.25;">Kiryat Atidim, Building 7</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">
              <div style="line-height: 1.25;">Tel Aviv, Israel</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">RE: <u>Chemomab Therapeutics Ltd.</u></div>
      <div style="text-align: center; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Ladies and Gentlemen:</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have acted as Israeli counsel to Chemomab Therapeutics Ltd, a company organized under the laws of the State of Israel (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;),
        in connection with the filing by the Company of a prospectus supplement (the &#8220;<font style="font-weight: bold;">Prospectus Supplement</font>&#8221;) to a registration statement on Form F-3 (the &#8220;<font style="font-weight: bold;">Registration Statement</font>&#8221;
        and the prospectus filed thereto, the &#8220;<font style="font-weight: bold;">Prior Prospectus</font>&#8221;, File No. 333-275002) with the Securities and Exchange Commission (the &#8220;<font style="font-weight: bold;">SEC</font>&#8221;) pursuant to Rule 415 promulgated
        under the Securities Act of 1933, as amended (the &#8220;<font style="font-weight: bold;">Securities Act</font>&#8221;), in connection with the Sales Agreement, dated as of October 16, 2023 (the &#8220;<font style="font-weight: bold;">Sales Agreement</font>&#8221;),
        entered into by and between the Company and Roth Capital Partners, LLC (the &#8220;<font style="font-weight: bold;">Agent</font>&#8221;). The Prospectus Supplement updates the amount of ADSs the Company is eligible to sell under General Instruction I.B.5 of
        Form F-3 such that the Company may sell ADSs having an aggregate offering price of up to $8,626,564 from time to time through the Agent.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This opinion letter is furnished to you at your request to enable you to fulfill the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act, in connection with
        the filing of the Registration Statement.</div>
      <div style="text-align: justify; text-indent: 28.35pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In connection herewith, we have examined the originals, or photocopies or copies, certified or otherwise identified to our satisfaction, of: (i) the form of the Registration
        Statement, to which this opinion letter is attached as an exhibit; (ii) a copy of the amended and restated articles of association of the Company, as currently in effect (the &#8220;<font style="font-weight: bold;">Articles</font>&#8221;); (iii) minutes of the
        meeting of the board of directors of the Company (the &#8220;<font style="font-weight: bold;">Board</font>&#8221;) at which the filing of the Registration Statement and the actions to be taken in connection therewith were approved; (iv) minutes of the meeting
        of the Board at which the execution of the Sales Agreement and the actions to be taken in connection therewith were approved; (v) minutes of the meeting of the Board at which the aggregate sales amount contemplated under the Prospectus Supplement
        were approved, and (vi) such other corporate records, agreements, documents and other instruments, and such certificates or comparable documents of public officials and of officers and representatives of the Company as we have deemed relevant and
        necessary as a basis for the opinions hereafter set forth. We have also made inquiries of such officers and representatives as we have deemed relevant and necessary as a basis for the opinions hereafter set forth.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In such examination, we have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of all documents submitted to us as originals,
        the conformity to original documents of all documents submitted to us as certified copies or confirmed as photostatic copies, and the authenticity of the originals of such latter documents. We have also assumed the truth of all facts communicated
        to us by the Company and that all minutes of meetings of the Board and the shareholders of the Company that have been provided to us are true and accurate and have been properly prepared in accordance with the Articles and all applicable laws.</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Based upon and subject to the foregoing, we are of the opinion that, assuming that prior to the issuance and sale of any of ADSs under the Sales Agreement, the price, number of
        ADSs and certain other terms of issuance with respect to any specific placement notice delivered under the Sales Agreement will be authorized and approved by the Board or a pricing committee of the Board in accordance with Israeli law, all
        corporate proceedings necessary for the authorization, issuance and delivery of the Ordinary Shares underlying the ADSs shall have been taken upon issuance pursuant to the terms of the Sales Agreement against payment of the consideration set forth
        in the Sales Agreement and in accordance with resolutions of the Board related to the Offering, the Ordinary Shares underlying the ADSs will be validly issued, fully paid and non-assessable and, are not subject to any preemptive rights, rights of
        first refusal or other similar rights of any securityholder of the Company pursuant to the Company&#8217;s currently effective Articles, Israeli law or the documents governed by the laws of the State of Israel.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">With respect to our opinion as to the Ordinary Shares underlying the ADSs, we have assumed that, at the time of issuance and sale and to the extent any such issuance would exceed
        the maximum share capital of the Company currently authorized, the number of Ordinary Shares that the Company is authorized to issue shall have been increased in accordance with the Articles such that a sufficient number of Ordinary Shares are
        authorized and available for issuance under the Articles.&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Members of our firm are admitted to the Bar in the State of Israel, and we do not express any opinion as to the laws of any other jurisdiction. This opinion is limited to the
        matters stated herein and no opinion is implied or may be inferred beyond the matters expressly stated.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We consent to the filing of this opinion as an exhibit to the Registration Statement (as an exhibit to a Report of Foreign Private Issuer on Form 6-K that is incorporated by
        reference in the Registration Statement) and to the reference to our firm appearing under the caption &#8220;Legal Matters&#8221; in the Prospectus. In giving this consent, we do not thereby admit that we are within the category of persons whose consent is
        required under Section&#160;7 of the Securities Act, the rules and regulations of the Commission promulgated thereunder or Item 509 of the Commission&#8217;s Regulation S-K under the Securities Act.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This opinion letter is rendered as of the date hereof and we disclaim any obligation to advise you of facts, circumstances, events or developments that may be brought to our
        attention after the date of the Registration Statement that may alter, affect or modify the opinions expressed herein.</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 100%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Very truly yours,</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; line-height: 1.25; font-style: italic;">/s/ Meitar | Law Offices</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Meitar | Law Offices</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;- 2 -</div>
      <div style="text-align: justify; line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div class="BRPFPageFooter">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !D F4# 2(  A$! Q$!_\0
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MO_?W_P"M0![O_P +\L/^@'=?]_EH_P"%^6'_ $ [K_O\M>$;[7_GA)_W]_\
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M<7_?K_Z] %ZBJ/DWW_/W%_WZ_P#KT>3??\_<7_?K_P"O0!>HJCY-]_S]Q?\
M?K_Z]'DWW_/W%_WZ_P#KT 7J*H^3??\ /W%_WZ_^O1Y-]_S]Q?\ ?K_Z] %Z
MBJ/DWW_/W%_WZ_\ KT>3??\ /W%_WZ_^O0!>HJCY-]_S]Q?]^O\ Z]'DWW_/
MU%_WZ_\ KT 7J*H^3??\_<7_ 'Z_^O1Y-]_S]Q?]^O\ Z] %ZBJ/DWW_ #]Q
M?]^O_KT>3??\_<7_ 'Z_^O0!>HJCY-]_S]Q?]^O_ *]'DWW_ #]Q?]^O_KT
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M(D^K9R<]ZZ^B@#G=+1AXTUQB&"F"W ..#PU+XR@NI;.RDLK62[DM[V*=HHV
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MH **** "BBB@ HHHH **** "BBB@ HHHH *S],_X_-2_Z[C_ - 6M"L_3/\
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MG\:MZ587&DWKPP1QO:W4S2NRC:(0(T4#'?)% &E_:41U&2R6.9I(XQ([!/E
M.<#/KQ54:_;MM58;HRF?[.8O+^96QNYYZ8YI+S2Y)-82^@:*)UB:,OM)9\@X
M!YQ@$YJBWAZ6315MI3;-=^9YK7&&SYA',@YSN_3'% &A-K]C#-=QRM(GV:-I
M7<I\I53AL'O@D9J1]8@3[-YD<ZF<;@"GW1D#+>G)%95[X;ENY+\27">5/!)$
M@*9(+D$EO7[O3WI]OH$\,%I")HBB;EE&PC@N&PGITQS0!JZ?JUM?S2QV_F9C
MSRRX#88J<?B#4LE[''>_9Y/E_<M,7)P  0#_ #K"TG1KC1[FZGMQ!*]Q)\P4
M%=P:0L6;GJ QZ>E:U]IHNKIY)"CQM;/;F-LX;<0>W;B@"PM_:,L;+<PD2 LA
M#CY@.I'K2?VC9F&.474/ERG:C^8,,?8UAQ:!=XMII+U&NH+::!)/+^Z78$8^
M@&*J+X2=EL_M$L,AAEF=XSO"LLF.ASG(Q^M '3Z?>"[$Y",OE3-"=Q')7O5N
MJ6G6IM!< L&\V9Y1@8QGM5V@ HHHH **** "L_3/^/S4O^NX_P#0%K0K/TS_
M (_-2_Z[C_T!: -"BBB@#Q+]IS_D&:#_ -=Y?_017A#?\>(_ZZG_ -!KW?\
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M;/50>H%9]K=W4O@Z5_M!243,GG22-M"B3&0W4KCO78A0.@ _"DV+C&T8],4
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M!ZQ_T&=/_P"_;T >1?9G_OQ?]_!1]E?^_%_W\%>N?\*#UC_H,Z?_ -^WI?\
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MU9HH K?;$_N3?]^C1]L3^Y-_WZ-6:* *WVQ/[DW_ 'Z-'VQ/[DW_ 'Z-6:*
M*WVM/[DW_?HU!IH;S[V0JRK)-N7<,9&T#^E:%&* "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
-HH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
